Apollomics Inc. Class A Ordinary Shares (APLM) - Total Liabilities
Based on the latest financial reports, Apollomics Inc. Class A Ordinary Shares (APLM) has total liabilities worth $9.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Apollomics Inc. Class A Ordinary Shares (APLM) long-term investment share to see how much of total assets are deployed in long-term investments.
Apollomics Inc. Class A Ordinary Shares - Total Liabilities Trend (2019–2025)
This chart illustrates how Apollomics Inc. Class A Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see APLM total asset value.
Apollomics Inc. Class A Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Apollomics Inc. Class A Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IFCA MSC Bhd
KLSE:0023
|
Malaysia | RM31.11 Million |
|
Tong-Hwa Synthetic Fiber Co Ltd
TW:1418
|
Taiwan | NT$4.10 Billion |
|
B&M European Value Retail SA
LSE:BME
|
UK | GBX3.17 Billion |
|
Yuyu Pharma Inc
KO:000227
|
Korea | ₩63.32 Billion |
|
SBF AG
F:CY1K
|
Germany | €17.86 Million |
|
Tate & Lyle PLC
LSE:TATE
|
UK | GBX2.07 Billion |
|
Next Science Ltd
AU:NXS
|
Australia | AU$10.02 Million |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
USA | $3.66 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Apollomics Inc. Class A Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See APLM net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apollomics Inc. Class A Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apollomics Inc. Class A Ordinary Shares (2019–2025)
The table below shows the annual total liabilities of Apollomics Inc. Class A Ordinary Shares from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.90 Million | +20.26% |
| 2024-12-31 | $8.23 Million | -41.82% |
| 2023-12-31 | $14.15 Million | -97.30% |
| 2022-12-31 | $524.60 Million | +55.99% |
| 2021-12-31 | $336.30 Million | +12.90% |
| 2020-12-31 | $297.87 Million | +113.11% |
| 2019-12-31 | $139.78 Million | -- |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more